GlassScriptPhysician profile
Veronika Leonenko
NPI 1306300199
$3,466.31
in general payments reported to CMS, 2019-2025
37 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $778 · 2022: $621 · 2023: $801 · 2024: $826 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054 · Entertainment: $13.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.24 |
| Entertainment | $13.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $600.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $329.85 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $290.94 | 2022 | |
| Pfizer INC. | $258.28 | 2021-2025 | |
| Amgen INC. | $207.35 | 2021-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $206.68 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $162.11 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $152.07 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $141.47 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.09 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $90.90 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.98 | 2021 | |
| Insightec,INC | $74.32 | 2023 | Exablate |
| Esperion Therapeutics, INC. | $73.02 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $63.90 | 2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronika Leonenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.